Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Fresenius Kabi

< Previous 1 2 Next >
Fresenius Kabi Submits 510(k) Notification for the Aurora Xi Plasmapheresis System Software Version 2.0 with New Nomogram
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Receives 2024 Novaplus Program Excellence Award from Vizient
From Fresenius Kabi
Via Business Wire
CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code and Pass-Through Payment Status for Tyenne® (tocilizumab-aazg)
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Inducts 12 into National Blood Donation Hall of Fame
From Fresenius Kabi
Via Business Wire
Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (ustekinumab-aauz)
From Fresenius Kabi
Via Business Wire
Fresenius Kabi and AABB Announce Start of 19th Annual Blood Collectors Week September 1-7, 2024
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Expands Women’s Health Portfolio with New Generic Option for Reproductive Health
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Receives 2024 Trailblazer Award From Premier Inc. for Supply Chain Innovation
From Fresenius Kabi
Via Business Wire
Arunesh Verma Joins Fresenius Kabi USA as President
From Fresenius Kabi
Via Business Wire
Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States
From Fresenius Kabi
Via Business Wire
Angels for Change 2024 Drug Shortage Guardian Award Presented to Fresenius Kabi USA
From Fresenius Kabi
Via Business Wire
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections
From Fresenius Kabi
Via Business Wire
Fresenius Kabi and Mayo Clinic Enter into Multiyear Supply and Service Agreement for the Ivenix® Infusion System
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Celebrates 25th Anniversary of National Blood Donation Hall of Fame by Honoring 2023 Heroes
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Introduces Smart Labels for Diprivan® with Embedded Fully Interoperable +RFID Technology
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Named 2023 Supplier Partner of the Year by Vizient
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Selected for Second Consecutive Year to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange
From Fresenius Kabi
Via Business Wire
Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi
From Fresenius Kabi
Via Business Wire
Fresenius Kabi and Lupagen Enter into Strategic Development and Supply Agreement to Bring Cell and Gene Therapies to the Bedside
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Launches Plerixafor Injection
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Introduces New Presentation for Fentanyl Citrate Injection, USP in Simplist® Ready-to-Administer Prefilled Syringes
From Fresenius Kabi
Via Business Wire
Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment
From Fresenius Kabi
Via Business Wire
IDACIO® (adalimumab-aacf) Now Available in the United States
From Fresenius Kabi
Via Business Wire
Metrodora Institute, a Leader in Treating Complex Conditions, Chooses the Ivenix Infusion System from Fresenius Kabi
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio
From Fresenius Kabi
Via Business Wire
Supporting Patient Safety: Fresenius Kabi Expands Ready-to-Administer Portfolio with Diazepam Injection, USP in Simplist® Prefilled Syringe
From Fresenius Kabi
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.